Quantitative Dynamic Models of Arthritis Progression in the Rat

PurposeThis comparison employs mathematical disease progression models to identify a rat model of arthritis with the least inter-animal variability and features lending to better study designs.MethodsArthritis was induced with either collagen (CIA) or mycobacterium (AIA) in either Lewis or Dark Agouti (DA) rats. Disease progression was monitored by paw edema and body weight. Models with production, loss, and feedback components were constructed and population analysis using NONMEM software was employed to identify inter-animal variability in the various disease progression parameters.ResultsOnset time was the only parameter different within all four groups (DA–AIA 11.5 days, DA–CIA 16.5 days, Lewis–AIA 11.9 days, Lewis–CIA 13.9 days). The loss-of-edema rate constant was 20% slower in DA (0.362 h−1) than Lewis (0.466 h−1) rats. Most models exhibited peak paw edema 20 days post-induction. Edema in CIA returned to 150% of the initial value after the disease peaked. DA rats displayed more severe overall responses.ConclusionsNo statistical differences between groups were observed for inter-animal variation in disease onset, progression and severity parameters. Onset time varies and should be noted in the design of future studies. DA rats may offer a more dynamic range of edema response than Lewis rats.

[1]  Mats O. Karlsson,et al.  Assessment of Actual Significance Levels for Covariate Effects in NONMEM , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[2]  R. Holmdahl,et al.  Identification of conformation-dependent epitopes and V gene selection in the B cell response to type II collagen in the DA rat. , 2001, International immunology.

[3]  R. Holmdahl,et al.  Arthritis induced in rats with non‐immunogenic adjuvants as models for rheumatoid arthritis , 2001, Immunological reviews.

[4]  T. Meert,et al.  Further evidence validating adjuvant arthritis as an experimental model of chronic pain in the rat. , 1982, Life sciences.

[5]  L. Klareskog,et al.  Homologous type II collagen-induced arthritis in rats. Characterization of the disease and demonstration of clinically distinct forms of arthritis in two strains of rats after immunization with the same collagen preparation. , 1990, Arthritis and rheumatism.

[6]  N. Bauman,et al.  Studies on type II collagen induced polyarthritis in rats. Effect of complement depletion. , 1981, Journal of immunopharmacology.

[7]  J. Radulovic,et al.  Behavior and Severity of Adjuvant Arthritis in Four Rat Strains , 2001, Brain, Behavior, and Immunity.

[8]  T. Hotokebuchi,et al.  Serum transfer of collagen arthritis in congenitally athymic nude rats. , 1985, Journal of immunology.

[9]  S. Kerwar,et al.  Type II collagen-induced arthritis in rats. , 1988, Methods in enzymology.

[10]  R. Holmdahl,et al.  Chronicity of arthritis induced with homologous type II collagen (CII) in rats is associated with anti-CII B-cell activation. , 1994, Journal of autoimmunity.

[11]  J. Stuart,et al.  Type II Collagen‐induced Arthritis , 1985, Annals of the New York Academy of Sciences.

[12]  I. Rioja,et al.  Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment , 2004, Clinical and experimental immunology.

[13]  Hansson,et al.  Cartilage oligomeric matrix protein (COMP)‐induced arthritis in rats , 1998, Clinical and experimental immunology.

[14]  S. Akilesh,et al.  The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. , 2004, The Journal of clinical investigation.

[15]  P. Wooley The usefulness and the limitations of animal models in identifying targets for therapy in arthritis. , 2004, Best practice & research. Clinical rheumatology.

[16]  S. Kerwar,et al.  Type II collagen-induced arthritis. Studies with purified anticollagen immunoglobulin. , 1983, Arthritis and rheumatism.

[17]  A. Kang,et al.  Autoimmunity to type II collagen an experimental model of arthritis , 1977, The Journal of experimental medicine.

[18]  L. Klareskog,et al.  Adjuvant oils induce arthritis in the DA rat. I. Characterization of the disease and evidence for an immunological involvement , 1991, Journal of Autoimmunity.

[19]  G. Kearns,et al.  Population Pharmacokinetic Model for Gatifloxacin in Pediatric Patients , 2007, Antimicrobial Agents and Chemotherapy.

[20]  A. Kang,et al.  Serum transfer of collagen-induced arthritis. II. Identification and localization of autoantibody to type II collagen in donor and recipient rats. , 1983, Arthritis and rheumatism.

[21]  J. Taurog,et al.  [31] Adjuvant arthritis , 1988 .

[22]  C. Pearson,et al.  Preparation of arthritogenic hydrosoluble peptidoglycans from both arthritogenic and non-arthritogenic bacterial cell walls , 1977, Infection and immunity.

[23]  F. Clayton,et al.  Induction of arthritis in DA rats by incomplete Freund's adjuvant. , 1993, The Journal of rheumatology.

[24]  A. Kang,et al.  Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis , 1982, The Journal of experimental medicine.

[25]  L. Klareskog,et al.  Increased serum levels of cartilage oligomeric matrix protein and bone sialoprotein in rats with collagen arthritis. , 1997, British journal of rheumatology.

[26]  R. Jonsson,et al.  Arthritis induced in rats with adjuvant oil is a genetically restricted, alpha beta T-cell dependent autoimmune disease. , 1992, Immunology.

[27]  I. Azuma,et al.  New model of a synthetic adjuvant, N-acetylmuramyl-L-alanyl-D-isoglutamine- induced arthritis: clinical and histologic studies in athymic nude and euthymic rats. , 1982, Laboratory investigation; a journal of technical methods and pathology.

[28]  R. Jones,et al.  Studies on adjuvant-induced polyarthritis in rats. I. Adjuvant composition, route of injection, and removal of depot site. , 1962, Arthritis and rheumatism.

[29]  G. Kingsley,et al.  The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. , 1992, Arthritis and rheumatism.

[30]  Lars Klareskog,et al.  Comparative susceptibility of DA, LEW, and LEW.1AV1 rats to arthritis induced with different arthritogens: mineral oil, mycobacteria, muramyl dipeptide, avridine and rat collagen type II. , 1997, Transplantation proceedings.

[31]  C. Pearson,et al.  Studies of polyarthritis and other lesions induced in rats by injection of mycobacterial adjuvant. I. General clinical and pathologic characteristics and some modifying factors , 1959 .

[32]  B. Kirkham,et al.  The in vivo effects of tumour necrosis factor blockade on the early cell mediated immune events and syndrome expression in rat adjuvant arthritis , 2002, Clinical and experimental immunology.

[33]  C. Pearson Development of Arthritis, Periarthritis and Periostitis in Rats Given Adjuvants.∗ , 1956, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[34]  M. Dallman,et al.  Immunisation against heterologous type II collagen induces arthritis in mice , 1980, Nature.